Surrozen, Inc./DE Unrealized Gain (Loss) on Investments
Surrozen, Inc./DE (SRZN) reported Unrealized Gain (Loss) on Investments of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2025-03-31
- Surrozen, Inc./DE unrealized gain (loss) on investments for the quarter ending 2024-12-31 was $0.00.
- Surrozen, Inc./DE unrealized gain (loss) on investments for the quarter ending 2024-09-30 was $0.00.
- Surrozen, Inc./DE unrealized gain (loss) on investments for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE unrealized gain (loss) on investments for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE unrealized gain (loss) on investments for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Surrozen, Inc./DE unrealized gain (loss) on investments for fiscal 2023 was $241.00K.
- Surrozen, Inc./DE unrealized gain (loss) on investments for fiscal 2022 was -$122.00K.
- Surrozen, Inc./DE unrealized gain (loss) on investments for fiscal 2021 was -$119.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 3 month as first filed | Unrealized Gain (Loss) on Investments 4 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | -$1.00K derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | -$1.00K derived: sum of 3 quarters · filed 2025-03-31 | -$5.00K derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | -$1.00K derived: sum of 2 quarters · filed 2025-03-31 | -$5.00K derived: sum of 3 quarters · filed 2025-03-31 | $50.00K derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$5.00K derived: sum of 2 quarters · filed 2025-03-31 | $50.00K derived: sum of 3 quarters · filed 2025-03-31 | $241.00K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$4.00K 10-Q · filed 2024-11-06 | $51.00K derived: sum of 2 quarters · filed 2024-11-06 | $242.00K 10-Q · filed 2024-11-06 | $425.00K derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $55.00K 10-Q · filed 2024-08-12 | $246.00K 10-Q · filed 2024-08-12 | $429.00K derived: sum of 3 quarters · filed 2024-08-12 | $481.00K derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $191.00K 10-Q · filed 2024-05-08 | $374.00K derived: sum of 2 quarters · filed 2024-05-08 | $426.00K derived: sum of 3 quarters · filed 2024-05-08 | $379.00K derived: sum of 4 quarters · filed 2024-05-08 | ||
| 2022-12-31 | $183.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $235.00K derived: sum of 2 quarters · filed 2024-04-10 | $188.00K derived: sum of 3 quarters · filed 2024-04-10 | -$122.00K 10-K · filed 2024-04-10 | ||
| 2022-09-30 | $52.00K 10-Q · filed 2023-11-08 | $5.00K derived: sum of 2 quarters · filed 2023-11-08 | -$305.00K 10-Q · filed 2023-11-08 | -$408.00K derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | -$47.00K 10-Q · filed 2023-08-09 | -$357.00K 10-Q · filed 2023-08-09 | -$460.00K derived: sum of 3 quarters · filed 2023-08-09 | -$476.00K derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | -$310.00K 10-Q · filed 2023-05-10 | -$413.00K derived: sum of 2 quarters · filed 2023-05-10 | -$429.00K derived: sum of 3 quarters · filed 2023-05-10 | -$429.00K derived: sum of 4 quarters · filed 2023-05-10 | ||
| 2021-12-31 | -$103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$119.00K derived: sum of 2 quarters · filed 2023-03-31 | -$119.00K derived: sum of 3 quarters · filed 2023-03-31 | -$119.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | -$16.00K 10-Q · filed 2022-11-14 | -$16.00K derived: sum of 2 quarters · filed 2022-11-14 | -$16.00K 10-Q · filed 2022-11-14 | -$16.00K derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | -$6.30K 10-Q · filed 2021-08-09 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2022-08-11 | $0.00 derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 | $6.30K 10-Q · filed 2021-05-24 | $0.00 derived: sum of 2 quarters · filed 2022-05-11 | $0.00 derived: sum of 3 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$8.39K 10-K/A · filed 2021-05-14 | $0.00 derived: sum of 2 quarters · filed 2022-03-28 | $0.00 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |